bradykinin, des-arg(9)- has been researched along with Angioneurotic Edema in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, A; Agostoni, A; Cugno, M; Gervais, N; Lepage, Y; Molinaro, G; Perez, M | 1 |
| Adam, A; Désormeaux, A; Moreau, ME | 1 |
| Adam, A; Blais, C; Brown, NJ; Friborg, J; Geadah, D; Gervais, N; Lepage, Y; Munoz, C; Rouleau, JL; Spence, D | 1 |
| Adam, A; Gervais, N; Molinaro, G | 1 |
1 review(s) available for bradykinin, des-arg(9)- and Angioneurotic Edema
| Article | Year |
|---|---|
[Physiopathology of the acute adverse effects of angiotensin-converting-enzyme inhibitors].
Topics: Acute Disease; Aminopeptidases; Anaphylaxis; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Drug Hypersensitivity; Genetic Predisposition to Disease; Humans; Hypotension; Leukocyte Reduction Procedures; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Bradykinin; Renal Dialysis; Transfusion Reaction | 2007 |
3 other study(ies) available for bradykinin, des-arg(9)- and Angioneurotic Edema
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.
Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Bradykinin; Female; Half-Life; Humans; Hypertension; Kinetics; Male; Mathematics; Models, Theoretical; Reference Values | 2002 |
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.
Topics: Adult; Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Lysine Carboxypeptidase; Male; Middle Aged | 1999 |
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Topics: Aminopeptidases; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Biotransformation; Bradykinin; Drug Hypersensitivity; Enalaprilat; Fibrinolysin; Fibrinolysis; Humans; Kininogen, High-Molecular-Weight; Male; Models, Biological; Plasma; Recombinant Proteins; Reference Values; Tissue Plasminogen Activator | 2002 |